These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 22068815)

  • 1. Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients.
    Romano S; Fratini S; Ricevuto E; Procaccini V; Stifano G; Mancini M; Di Mauro M; Ficorella C; Penco M
    Br J Cancer; 2011 Nov; 105(11):1663-8. PubMed ID: 22068815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series.
    Cil T; Kaplan AM; Altintas A; Akin AM; Alan S; Isikdogan A
    Clin Drug Investig; 2009; 29(2):131-7. PubMed ID: 19133708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.
    Sawaya H; Sebag IA; Plana JC; Januzzi JL; Ky B; Tan TC; Cohen V; Banchs J; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
    Circ Cardiovasc Imaging; 2012 Sep; 5(5):596-603. PubMed ID: 22744937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide.
    van Boxtel W; Bulten BF; Mavinkurve-Groothuis AM; Bellersen L; Mandigers CM; Joosten LA; Kapusta L; de Geus-Oei LF; van Laarhoven HW
    Biomarkers; 2015 Mar; 20(2):143-8. PubMed ID: 25980453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum NT-proBNP in the early detection of doxorubicin-induced cardiac dysfunction.
    Kittiwarawut A; Vorasettakarnkij Y; Tanasanvimon S; Manasnayakorn S; Sriuranpong V
    Asia Pac J Clin Oncol; 2013 Jun; 9(2):155-61. PubMed ID: 22897825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term heart function after adjuvant epirubicin chemotherapy for breast cancer.
    Appel JM; Zerahn B; Møller S; Christensen HM; Søgaard P; Ejlertsen B; Fogh-Andersen N; Jensen BV; Nielsen DL
    Acta Oncol; 2012 Nov; 51(8):1054-61. PubMed ID: 22909389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBG 84 Trial.
    Rüger AM; Schneeweiss A; Seiler S; Tesch H; van Mackelenbergh M; Marmé F; Lübbe K; Sinn B; Karn T; Stickeler E; Müller V; Schem C; Denkert C; Fasching PA; Nekljudova V; Garfias-Macedo T; Hasenfuß G; Haverkamp W; Loibl S; von Haehling S
    J Am Heart Assoc; 2020 Dec; 9(23):e018143. PubMed ID: 33191846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.
    Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B
    J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab.
    Ky B; Putt M; Sawaya H; French B; Januzzi JL; Sebag IA; Plana JC; Cohen V; Banchs J; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
    J Am Coll Cardiol; 2014 Mar; 63(8):809-16. PubMed ID: 24291281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of lecithinized human recombinant super oxide dismutase as cardioprotectant in anthracycline-treated breast cancer patients.
    Broeyer FJ; Osanto S; Suzuki J; de Jongh F; van Slooten H; Tanis BC; Bruning T; Bax JJ; Ritsema van Eck HJ; de Kam ML; Cohen AF; Mituzhima Y; Burggraaf J
    Br J Clin Pharmacol; 2014 Nov; 78(5):950-60. PubMed ID: 24844787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
    Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
    Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of 10-year changes in levels of N-terminal pro B-type natriuretic peptide and cardiac troponin I in the elderly.
    Eggers KM; Lindahl B; Venge P; Lind L
    Int J Cardiol; 2018 Apr; 257():300-305. PubMed ID: 29506712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patients treated with cardiotoxic chemotherapy.
    Kouloubinis A; Kaklamanis L; Ziras N; Sofroniadou S; Makaritsis K; Adamopoulos S; Revela I; Athanasiou A; Mavroudis D; Georgoulias V
    Int J Cardiol; 2007 Nov; 122(3):195-201. PubMed ID: 17289172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic modelling of acute N-terminal pro B-type natriuretic peptide after doxorubicin infusion in breast cancer.
    Liang S; Brundage RC; Jacobson PA; Blaes A; Kirstein MN
    Br J Clin Pharmacol; 2016 Sep; 82(3):773-83. PubMed ID: 27128712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
    Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
    J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients.
    Blancas I; Martín-Pérez FJ; Garrido JM; Rodríguez-Serrano F
    Breast; 2020 Dec; 54():106-113. PubMed ID: 32977298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification.
    Ferraro MP; Gimeno-Vazquez E; Subirana I; Gómez M; Díaz J; Sánchez-González B; García-Pallarols F; Martínez L; Ble M; Molina L; Belarte LC; Abella E; Elosua R; Comín-Colet J; Salar A
    Eur J Haematol; 2019 Jun; 102(6):509-515. PubMed ID: 30972815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia.
    Horácek JM; Pudil R; Tichý M; Jebavý L; Strasová A; Praus R; Zák P; Malý J
    Neoplasma; 2005; 52(5):430-4. PubMed ID: 16151589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial.
    Antunes P; Esteves D; Nunes C; Sampaio F; Ascensão A; Vilela E; Teixeira M; Amarelo AL; Joaquim A
    Trials; 2019 Jul; 20(1):433. PubMed ID: 31307527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiotoxicity of anthracycline (ANT) treatment in children with malignant tumors.
    Hu H; Zhang W; Huang D; Yang Q; Li J; Gao Y
    Pediatr Hematol Oncol; 2018 Mar; 35(2):111-120. PubMed ID: 29648903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.